Abstract
The survey presents the last inovations in diagnostic, monitoring and therapy of the prostate cancer. Prostate cancer becomes by the time androgen independent and is called castrate resistent prostate cancer.
The novel drug abiterone acetate brings the chance to influences this form of prostate cancer.